30
total announcements
544319.BO · 15 min delayed
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has published a newspaper advertisement for its 9th Annual General Meeting, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, as required by SEBI regulations.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has submitted its Annual Report for the financial year 2025-26, including the Notice convening the 9th Annual General Meeting (AGM) and Business Responsibility and Sustainability Report. The AGM will be held on September 25, 2026, through video conferencing.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has announced the notice convening the 9th Annual General Meeting (AGM) and Annual Report for the financial year 2025-26, scheduled to be held on September 25, 2026, through video conferencing.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the Exchange about an Analyst/ Institutional Investor Meet scheduled to be held on September 02, 2026, at Mumbai.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the Exchange regarding the newspaper publication for the pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the Exchange regarding the appointment of Independent Director, Mr. Viranchi Arvindbhai Shah, and other key managerial personnel. The company has also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and proposed incorporation of subsidiaries in Mexico and Canada.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the Exchange regarding the appointment of Company Secretary and Compliance Officer, appointment of Non-Executive Additional Director, approval of ESOS 2026, and proposed incorporation of subsidiaries in Mexico and Canada.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the Exchange regarding proposed incorporation of Subsidiary Company in Canada. The Board of Directors have accorded their approval for incorporation of a Subsidiary Company in Canada to support the Company's business and strategic objectives in the Canadian and other international markets.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the Exchange regarding proposed incorporation of Wholly owned subsidiary in Mexico, Subsidiary Company in Canada, and other strategic objectives.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Limited has informed the Exchange about the outcome of its Board Meeting held on August 26, 2026. The Board has approved the appointment of a Company Secretary and Compliance Officer, a Non-Executive Additional Director, and authorized officers to determine materiality of events and make disclosures to stock exchanges. The Board has also approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 and proposed the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the exchange about giving a corporate guarantee for credit facilities availed by its subsidiary Apnar Pharma Private Limited from ICICI Bank Limited for an amount of INR 62 Crores.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the exchange about an analyst/institutional investor meet scheduled for August 25, 2026, where company officials will discuss publicly available information.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhananjay Barot, indicating a potential substantial acquisition of shares.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Ashokkumar Vijaysinh Barot.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the Exchange regarding the Scrutinizer Report dated August 04, 2026, for the Postal Ballot process conducted through remote e-voting. The shareholders have passed the Ordinary and Special Resolutions with requisite majority.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the exchange about the outcome of its postal ballot, where shareholders have passed the ordinary and special resolutions with the requisite majority.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Limited has announced its Q1FY27 earnings conference call transcript, highlighting a healthy performance despite an uncertain operating environment. The company's diversified business portfolio and operational excellence enabled it to deliver consistent business performance and reinforce its long-term growth trajectory.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the Exchange regarding Newspaper Publication Extracts of Unaudited Financial Results of the Company for quarter ended June 30, 2026.
Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd has informed the BSE regarding the audio recording of its earnings conference call for the quarter ended June 30, 2026, which is available on its website.